Elevated Serum or Plasma Potassium
An artifactually high value can occur with hemolysis of red blood cells (RBCs) during venipuncture, especially if there is prolonged tourniquet use and fist clenching during the drawing of the blood or at any time prior to potassium measurement.
An artifactually high potassium value can also occur when there are greater than 1,000,000 /µL platelets or greater than 100,000/µL white blood cells (WBCs).
Renal failure from any cause, with oliguria, or as chronic nonoliguric renal failure.
Excess potassium supplements, potassium-rich foods, salt substitutes, intravenous (IV) potassium, or infusion of potassium-containing drugs, such as potassium penicillin.
Hypoaldosteronism from Addison's disease or hypofunction of the renin-angiotensin-aldosterone system.
Acute acidosis from diabetic ketoacidosis or from lactic acidosis as found with extensive crush injury, burns, or tissue necrosis.
Ingestion of drugs that inhibit potassium secretion by the kidney.
All of these situations are especially dangerous if the potassium becomes extremely elevated.
Values greater than 7.5 mEq/L are associated with serious cardiac conduction abnormalities.
Commonly Encountered Situations
Hyperkalemia is found frequently in renal failure.
The most common cause of an artifactually elevated potassium is hemolysis of RBCs.
Suggested Additional Lab Testing
Determine whether the serum or plasma showed evidence of hemolysis by a change in color from yellow to pink or red.
Complete blood count (CBC) to assess platelet count and WBC count.
Evidence of renal disease from an elevated creatinine or blood urea nitrogen (BUN), or decreased urine output.
Serum aldosterone to assess for hypoaldosteronism.
Blood gases to evaluate possible acidosis.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|